Tags

Type your tag names separated by a space and hit enter

Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study.
Med Sci Monit 2009; 15(7):PH85-91MS

Abstract

BACKGROUND

Influenza vaccination is recommended for patients with cardiovascular diseases. The main reason for the low vaccination rates in such patients is insufficient knowledge about vaccination efficacy, including immune response to the vaccine. The aim of this study was to assess humoral response to influenza vaccination in patients with coronary artery disease.

MATERIAL/METHODS

This was a substudy of the randomized prospective double-blind placebo-controlled FLUCAD study on influenza vaccination in the secondary prevention of ischemic coronary events in patients with coronary artery disease. Patients received inactivated subunit vaccine (n=325) or placebo (n=333). Anti-hemagglutinin and anti-neuraminidase antibody levels to the vaccine strains as well as IgM and IgG levels against influenza A and B were measured before administration of vaccine/placebo and after 8-10 weeks in 78 vaccinated and 97 placebo patients.

RESULTS

Post-vaccination antibody titers were significantly higher than before vaccination, with mean increases of 4.9- to 5.7-fold for anti-hemagglutinin and 3.5- to 4.2-fold for neuraminidase antibodies. Post-vaccination protection rates ranged from 56.4 to 60.3% and response rates from 62.8 to 68%. The percentage of patients with significant post-vaccination concentrations of IgG and IgM was higher than before vaccination and amounted to 100% and 88.1% in the case of IgG and 14.3% and 5.2% in the case of IgM in response to influenza A and B, respectively.

CONCLUSIONS

At least 60% of the patients achieved high post-vaccination antibody levels sufficient to prevent influenza.

Authors+Show Affiliations

National Influenza Center (NIC), National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19564837

Citation

Brydak, Lidia B., et al. "Antibody Response to Influenza Vaccine in Coronary Artery Disease: a Substudy of the FLUCAD Study." Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, vol. 15, no. 7, 2009, pp. PH85-91.
Brydak LB, Romanowska M, Nowak I, et al. Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study. Med Sci Monit. 2009;15(7):PH85-91.
Brydak, L. B., Romanowska, M., Nowak, I., Ciszewski, A., & Bilińska, Z. T. (2009). Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 15(7), pp. PH85-91.
Brydak LB, et al. Antibody Response to Influenza Vaccine in Coronary Artery Disease: a Substudy of the FLUCAD Study. Med Sci Monit. 2009;15(7):PH85-91. PubMed PMID: 19564837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody response to influenza vaccine in coronary artery disease: a substudy of the FLUCAD study. AU - Brydak,Lidia B, AU - Romanowska,Magdalena, AU - Nowak,Iwona, AU - Ciszewski,Andrzej, AU - Bilińska,Zofia T, PY - 2009/7/1/entrez PY - 2009/7/1/pubmed PY - 2009/9/3/medline SP - PH85 EP - 91 JF - Medical science monitor : international medical journal of experimental and clinical research JO - Med. Sci. Monit. VL - 15 IS - 7 N2 - BACKGROUND: Influenza vaccination is recommended for patients with cardiovascular diseases. The main reason for the low vaccination rates in such patients is insufficient knowledge about vaccination efficacy, including immune response to the vaccine. The aim of this study was to assess humoral response to influenza vaccination in patients with coronary artery disease. MATERIAL/METHODS: This was a substudy of the randomized prospective double-blind placebo-controlled FLUCAD study on influenza vaccination in the secondary prevention of ischemic coronary events in patients with coronary artery disease. Patients received inactivated subunit vaccine (n=325) or placebo (n=333). Anti-hemagglutinin and anti-neuraminidase antibody levels to the vaccine strains as well as IgM and IgG levels against influenza A and B were measured before administration of vaccine/placebo and after 8-10 weeks in 78 vaccinated and 97 placebo patients. RESULTS: Post-vaccination antibody titers were significantly higher than before vaccination, with mean increases of 4.9- to 5.7-fold for anti-hemagglutinin and 3.5- to 4.2-fold for neuraminidase antibodies. Post-vaccination protection rates ranged from 56.4 to 60.3% and response rates from 62.8 to 68%. The percentage of patients with significant post-vaccination concentrations of IgG and IgM was higher than before vaccination and amounted to 100% and 88.1% in the case of IgG and 14.3% and 5.2% in the case of IgM in response to influenza A and B, respectively. CONCLUSIONS: At least 60% of the patients achieved high post-vaccination antibody levels sufficient to prevent influenza. SN - 1643-3750 UR - https://www.unboundmedicine.com/medline/citation/19564837/Antibody_response_to_influenza_vaccine_in_coronary_artery_disease:_a_substudy_of_the_FLUCAD_study_ L2 - https://www.medscimonit.com/download/index/idArt/869693 DB - PRIME DP - Unbound Medicine ER -